SCHEDULE: Activist Group Proposes $7M Private Placement for Alaunos

A group of investors led by Adrian Price has proposed a $7 million private placement in Alaunos Therapeutics, Inc., seeking Board engagement and a director appointment.

Summary

• An amendment to Schedule 13D has been filed by a group of 20 reporting persons, including Adrian Price and three holding companies (Hexagon ONE Inc, Alimenta Holding Inc, Krakatau Holding Inc), regarding their beneficial ownership in Alaunos Therapeutics, Inc.
• The reporting persons collectively beneficially own 189,061 shares of common stock, representing 8.6% of the class.
• On February 24, 2026, Adrian Price sent a letter to Alaunos Therapeutics' Board of Directors proposing a private placement of $7,000,000 in equity or equity-linked securities to be purchased by Hexagon ONE Inc, Alimenta Holding Inc, and Krakatau Holding Inc.
• The proposed private placement's purchase price would be negotiated based on market conditions, the company's liquidity needs, and long-term shareholder alignment.
• The group requested the Board meet with Adrian Price within five business days to begin term sheet negotiations and due diligence.
• The letter reiterated the group's nomination of Gerald Bruce to the Board and requested his appointment as a director.
• The reporting persons indicated that if the Board does not engage meaningfully within the five-business-day period, they may seek to purchase additional shares in the market or undertake a tender offer.
• The group also mentioned the possibility of an investor relations campaign if the Board fails to engage.
• The proposed private placement is anticipated to result in a change of control of Alaunos Therapeutics, Inc.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, as it introduces a potential capital infusion and activist pressure for shareholder value, but also carries the risk of a contentious situation and uncertainty regarding the terms and outcome of the proposed transaction.

Positives

• The proposed $7,000,000 private placement could provide a significant capital infusion for Alaunos Therapeutics, Inc.
• The investors' stated intention is to help create shareholder value, suggesting a focus on improving company performance.
• The proposal includes a request for Board engagement, which could lead to constructive dialogue and strategic alignment.

Negatives

• The proposal includes a threat of further market purchases or a tender offer if the Board does not engage, indicating potential for a contentious situation.
• The anticipated change of control could lead to significant disruption in company strategy and operations.
• The private placement terms, including the purchase price, are yet to be negotiated, introducing uncertainty regarding the valuation and dilution impact.

Risks

• Failure of the Board to engage meaningfully with the reporting persons could escalate the situation, potentially leading to a proxy fight, tender offer, or increased market volatility.
• The negotiation of the private placement terms may not result in mutually agreeable definitive documentation, causing the deal to fall through.
• Shareholder approval, if required by Nasdaq rules, introduces a contingency that could delay or prevent the closing of the private placement.
• A change of control could lead to significant shifts in management, strategy, and operational focus, which may not align with all existing shareholder interests.

Future Outlook

The reporting persons intend to continue their efforts to create shareholder value and reserve the right to purchase or sell additional common stock. If the Board does not engage within five business days, they may pursue further market purchases, a tender offer, or an investor relations campaign. The proposed private placement, if consummated, is expected to result in a change of control for the company.

Management Comments

• Adrian Price, on behalf of the Reporting Persons, proposed a private placement of $7,000,000 in securities to the Board of Directors.
• The Reporting Persons reiterated their nomination of Gerald Bruce to the Board and requested his appointment as a director.
• The Reporting Persons stated that if the Board does not engage meaningfully within five business days, they may seek to purchase additional shares or undertake a tender offer.
• The Reporting Persons intend to continue their efforts to help create shareholder value.

Industry Context

StockSavvy.ai notes that activist investor campaigns, particularly those involving proposals for significant capital injections and board representation, are common in the biotechnology and pharmaceutical sectors where companies often require substantial funding for R&D and commercialization. Such actions can signal either a perceived undervaluation by the activist or a belief that current management is not maximizing shareholder returns. The threat of a tender offer or increased market purchases indicates a strong commitment to their proposed changes.

Comparison to Industry Standards

• StockSavvy.ai observes that a proposed $7 million private placement for a company like Alaunos Therapeutics, Inc. (a biotechnology firm) is a moderate capital infusion. For comparison, similar-stage biotech companies often seek larger rounds, sometimes tens or hundreds of millions, depending on their clinical trial phases and burn rate. For instance, a Series B funding round for a biotech company can range from $20 million to $100 million.
• The demand for a board seat and the threat of further action if the board does not engage is a standard tactic for activist investors, similar to actions seen with Carl Icahn's involvement with various companies or Starboard Value's campaigns, which often begin with private letters and escalate to public pressure or proxy contests if demands are not met.
• The proposed change of control, if realized, would be a significant event, comparable to acquisitions or strategic mergers seen in the biotech space, such as Gilead Sciences' acquisition of Kite Pharma for $11.9 billion, which fundamentally altered Kite's strategic direction and ownership.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for increased shareholder value through capital infusion and activist oversight, but also risk of dilution from the private placement and potential for stock price volatility due to activist actions.
• Board of Directors: Faces immediate pressure to engage with the activist group and consider their proposals, including a director appointment and a significant capital raise.
• Management: Potential for strategic shifts and increased scrutiny if the activist group gains influence or control.
• Creditors: A capital raise could improve the company's financial stability, potentially benefiting creditors.

Next Steps

• Alaunos Therapeutics' Board of Directors is requested to meet with Adrian Price within five business days to begin term sheet negotiation and due diligence.
• The Board is requested to appoint Gerald Bruce as a director.
• If the Board does not engage meaningfully, the reporting persons may purchase additional shares in the market or undertake a tender offer.
• The reporting persons may also undertake an investor relations campaign if the Board does not engage.

Key Dates

Recommendation

The filing presents a mixed bag of potential outcomes. While a $7 million capital injection could be beneficial for Alaunos Therapeutics, the activist nature of the proposal, including the demand for a board seat and the threat of further action, introduces significant uncertainty and potential for conflict. The anticipated change of control could lead to substantial strategic shifts. Investors should hold to observe how the Board responds to the proposal and the subsequent developments, as the situation could evolve rapidly with both upside potential from a successful capital raise and downside risk from a protracted activist battle or unfavorable deal terms.

Keywords

Alaunos Therapeutics, Schedule 13D, Activist Investor, Private Placement, Change of Control, Board Nomination, Shareholder Value, Equity Investment, Tender Offer, Corporate Governance